Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Carcinoma, Renal Cell × Sorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Hepatocellular 5 Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

Sunitinib 6 pembrolizumab 3 Nivolumab 3 cabozantinib 2 Ipilimumab 2 Everolimus 2 Axitinib 2 sacituzumab govitecan 1 lenvatinib 1 entrectinib 1 belzutifan 1 avelumab 1 Sorafenib 1 Saline Solution 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02627963 2023-07-18

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

AVEO Pharmaceuticals, Inc.

Phase 3 Completed

350 enrolled 14 charts 1 FDA

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡